A Phase 1/2, multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subjects with newly diagnosed multiple myeloma (NDMM)

Trial Profile

A Phase 1/2, multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subjects with newly diagnosed multiple myeloma (NDMM)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Durvalumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 10 Jul 2017 Planned number of patients changed from 138 to 120.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 According to trial design presented at 53rd Annual Meeting of the American Society of Clinical Oncology, 15 patients have been enrolled till date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top